D'Amico P - Search Results

1

Targeting the microenvironment in solid tumors.

Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G. Belli C, et al. Cancer Treat Rev. 2018 Apr;65:22-32. doi: 10.1016/j.ctrv.2018.02.004. Epub 2018 Feb 22. Cancer Treat Rev. 2018. PMID: 29502037 Review.

2

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.

Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA. Hensing WL, et al. Among authors: d amico p. Clin Cancer Res. 2023 Aug 15;29(16):3092-3100. doi: 10.1158/1078-0432.CCR-22-3785. Clin Cancer Res. 2023. PMID: 37265453

3

Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Duso BA, et al. Expert Opin Pharmacother. 2018 Feb;19(3):299-305. doi: 10.1080/14656566.2018.1429407. Epub 2018 Jan 22. Expert Opin Pharmacother. 2018. PMID: 29355400

4

Liver toxicity in the era of immune checkpoint inhibitors: A practical approach.

Belli C, Zuin M, Mazzarella L, Trapani D, D'Amico P, Guerini-Rocco E, Achutti Duso B, Curigliano G. Belli C, et al. Crit Rev Oncol Hematol. 2018 Dec;132:125-129. doi: 10.1016/j.critrevonc.2018.09.019. Epub 2018 Oct 3. Crit Rev Oncol Hematol. 2018. PMID: 30447917 Review.

5

Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.

Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Morganti S, et al. Crit Rev Oncol Hematol. 2019 Jan;133:171-182. doi: 10.1016/j.critrevonc.2018.11.008. Epub 2018 Nov 26. Crit Rev Oncol Hematol. 2019. PMID: 30661654 Review.

6

The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review.

Mazzarella L, Duso BA, Trapani D, Belli C, D'Amico P, Ferraro E, Viale G, Curigliano G. Mazzarella L, et al. Eur J Cancer. 2019 Aug;117:14-31. doi: 10.1016/j.ejca.2019.04.035. Epub 2019 Jun 21. Eur J Cancer. 2019. PMID: 31229946 Review.

7

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.

Abdel-Aziz AK, Saadeldin MK, D'Amico P, Orecchioni S, Bertolini F, Curigliano G, Minucci S. Abdel-Aziz AK, et al. Eur J Cancer. 2019 Nov;122:22-41. doi: 10.1016/j.ejca.2019.08.013. Epub 2019 Oct 10. Eur J Cancer. 2019. PMID: 31606656 Review.

8

Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.

Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Morganti S, et al. Adv Exp Med Biol. 2019;1168:9-30. doi: 10.1007/978-3-030-24100-1_2. Adv Exp Med Biol. 2019. PMID: 31713162 Review.

9

Pharmacological management of male breast cancer.

Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Duso BA, et al. Expert Opin Pharmacother. 2020 Aug;21(12):1493-1504. doi: 10.1080/14656566.2020.1763305. Epub 2020 Jun 4. Expert Opin Pharmacother. 2020. PMID: 32496137 Review.

10

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity.

Mazzarella L, Giugliano S, D'Amico P, Belli C, Duso BA, Rescigno M, Curigliano G. Mazzarella L, et al. Eur J Cancer. 2020 Dec;141:218-224. doi: 10.1016/j.ejca.2020.10.006. Epub 2020 Nov 10. Eur J Cancer. 2020. PMID: 33186857

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters